RnRMarketResearch.com adds “Cosentyx (secukinumab) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023” to its store.

Dallas, TX -- (SBWire) -- 03/17/2015 --Novartis is developing a novel, SC, fully-human, IL-17A mAb known as Cosentyx (secukinumab, previously known as AIN457) for multiple indications, including RA. It is currently in Phase III clinical trials for RA in various countries, including the US, EU, and Japan. It prevents inflammatory responses, as it neutralizes IL-17A, resulting in the prevention of bone loss. As of November 2014, Cosentyx is currently undergoing regulatory review for psoriasis and in development for uveitis, psoriatic arthritis, ankylosing spondylitis, and asthma. Complete report is available at http://www.rnrmarketresearch.com/cosentyx-secukinumab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Scope
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cosentyx including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cosentyx for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and India.

Order a copy of this report at (Prices start at US $ 3495 for a single user PDF) http://www.rnrmarketresearch.com/contacts/purchase?rname=312805 .

Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Cosentyx performance.
- Obtain sales forecast for Cosentyx from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK and Japan and India).

1.1 List of Tables
Table 1: Symptoms of RA 19
Table 2: 1987 ACR Diagnostic Criteria for RA 22
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 23
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 26
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 29
Table 6: EULAR 2013 Criteria for RA Remission 30
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 34
Table 8: Leading Branded Treatments for RA 2014 41
Table 9: Unmet Need and Opportunity in RA, 2014 43
Table 10: Comparison of Therapeutic Drug Classes in Development for RA, 2014 61
Table 11: Product Profile - Cosentyx 64
Table 12: Cosentyx SWOT Analysis, 2014 67
Table 13: Global Sales Forecasts ($m) for Cosentyx, 2013-2023 68
Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 81

1.2 List of Figures
Figure 1: Normal Synovial Joint and Synovial Joint with RA 16
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 18
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 30
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 31
Figure 5: Flowchart for the Management of RA - EULAR 2013 32
Figure 6: RA - Phase II-III Pipeline, 2014 56
Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023 60
Figure 8: Clinical and Commercial Positioning of Cosentyx 66

Explore more reports on Arthritis Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/arthritis-drugs.